- Home
- GMAB vs BXP Comparison
GMAB vs BXP Comparison
Compare GMAB & BXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- BXP
- Stock Information
- Founded
- GMAB 1999
- BXP 1970
- Country
- GMAB Denmark
- BXP United States
- Employees
- GMAB N/A
- BXP N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- BXP Real Estate Investment Trusts
- Sector
- GMAB Health Care
- BXP Real Estate
- Exchange
- GMAB Nasdaq
- BXP Nasdaq
- Market Cap
- GMAB 12.1B
- BXP 11.6B
- IPO Year
- GMAB N/A
- BXP 1997
- Fundamental
- Price
- GMAB $22.34
- BXP $68.85
- Analyst Decision
- GMAB Buy
- BXP Buy
- Analyst Count
- GMAB 9
- BXP 13
- Target Price
- GMAB $40.71
- BXP $82.23
- AVG Volume (30 Days)
- GMAB 1.9M
- BXP 1.2M
- Earning Date
- GMAB 02-12-2025
- BXP 01-28-2025
- Dividend Yield
- GMAB N/A
- BXP 5.74%
- EPS Growth
- GMAB 83.82
- BXP N/A
- EPS
- GMAB 16.85
- BXP 0.09
- Revenue
- GMAB $2,988,286,182.00
- BXP $3,048,054,000.00
- Revenue This Year
- GMAB $18.78
- BXP N/A
- Revenue Next Year
- GMAB $14.98
- BXP $3.26
- P/E Ratio
- GMAB $13.00
- BXP $844.04
- Revenue Growth
- GMAB 30.67
- BXP N/A
- 52 Week Low
- GMAB $18.64
- BXP $56.46
- 52 Week High
- GMAB $31.88
- BXP $90.11
- Technical
- Relative Strength Index (RSI)
- GMAB 65.39
- BXP 38.57
- Support Level
- GMAB $18.74
- BXP $69.40
- Resistance Level
- GMAB $22.55
- BXP $72.55
- Average True Range (ATR)
- GMAB 0.46
- BXP 1.69
- MACD
- GMAB 0.39
- BXP -0.16
- Stochastic Oscillator
- GMAB 94.64
- BXP 13.57
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About BXP Boston Properties Inc.
BXP Inc. owns over 180 properties consisting of approximately 53 million rentable square feet of space. The portfolio is dominated by office buildings and is spread across major cities such as New York, Boston, San Francisco, Los Angeles, Seattle, and the Washington, D.C., region. The real estate investment trust also owns limited retail, hotel, and residential properties.